eXoZymes Inc.
NASDAQ: EXOZ
eXoZymes Inc. (Nasdaq: EXOZ) is a biotechnology company that has developed a new way to produce chemicals without using living cells. The company's technology, called "exozymes," combines enzymes (proteins that speed up chemical reactions) with artificial intelligence to create a manufacturing platform that transforms biomass into chemicals, medicines, and fuels. Unlike traditional synthetic biology that relies on living cells, eXoZymes' cell-free approach operates more like industrial chemistry, avoiding the common problems that prevent biological manufacturing from reaching commercial scale.
Investor Presentation
eXoZymes (Nasdaq: EXOZ) CEO Michael Heltzen frames the company’s platform as a new form of chemistry with applications across nutraceuticals and pharmaceuticals.
eXoZymes Inc. (NASDAQ: EXOZ) CEO Michael Heltzen appeared on The Upside to discuss the company’s cell-free biomanufacturing platform, its focus on NCT, and the broader opportunity to apply AI-engineered enzymes outside the cell.
eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1.
Asked about eXoZymes’ growth potential, Heltzen says the company is “here to make it really, really large” and describes the platform as “a new form of chemistry.”
In the full interview, Heltzen discusses NCT, a naturally occurring molecule found in black pepper, and explains how eXoZymes’ platform is designed to produce compounds at scale. He also describes the company’s dual-track opportunity: an over-the-counter nutraceutical path for natural NCT and a pharmaceutical path for more potent analogs.
eXoZymes is a Monrovia, California-based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to transform sustainable feedstocks into high-value compounds. The company is currently focused on products including NCT, non-intoxicating cannabinoids, and other applications where its platform may offer advantages in speed, purity, and scalability.
Learn more at https://exozymes.com. For investor inquiries, visit https://exozymes.com/investor.
Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.
eXoZymes Inc. (NASDAQ: EXOZ) CEO Michael Heltzen appeared on The Upside to discuss the company’s cell-free biomanufacturing platform, its focus on NCT, and the broader opportunity to apply AI-engineered enzymes outside the cell.
eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1.
Asked about eXoZymes’ growth potential, Heltzen says the company is “here to make it really, really large” and describes the platform as “a new form of chemistry.”
In the full interview, Heltzen discusses NCT, a naturally occurring molecule found in black pepper, and explains how eXoZymes’ platform is designed to produce compounds at scale. He also describes the company’s dual-track opportunity: an over-the-counter nutraceutical path for natural NCT and a pharmaceutical path for more potent analogs.
eXoZymes is a Monrovia, California-based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to transform sustainable feedstocks into high-value compounds. The company is currently focused on products including NCT, non-intoxicating cannabinoids, and other applications where its platform may offer advantages in speed, purity, and scalability.
Learn more at https://exozymes.com. For investor inquiries, visit https://exozymes.com/investor.
Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.
Read more
B2i Digital
May 8
Jinbei Li
May 13
ENZIDIA and DTU - Technical University of Denmark have signed an exclusive licensing agreement for the commercialization of the MillionFull technology!
MillionFull is a technology for obtaining massive full-length enzyme sequence-to-performance datasets, capable of gathering millions of datapoints each run.
The development was motivated by the data drought holding back the exciting potential of AI for enzyme acceleration. The solution came together while I was working as a postdoc at DTU Biosustain. The dataset from the demo run, with >100,000 data points, was open-sourced half a year ago.
With the licensing agreement, we can now apply it to solve real-world problems in biomanufacturing.
Great thanks to Morten Birkeland, our IP advisor, for representing Enzidia in the licensing term discussions, so that we could get to a fair deal structure quickly with clear rationales. I got to learn so much by being the student in the process!
Many thanks to Jens Kindtler and other colleagues on the DTU side for a smooth agreement forming process. We got to see first-hand how DTU executes its mission of "technology for people & society" by supporting research translation.
Great appreciation to Dr. Lei Yang, Prof. Alex Toftgaard Nielsen for their support with scientific input and resources. This work would not have been possible without your recognition and support of new ideas.
Thanks to Bjarke Erichsen and Simon Richter Krarup for helping make the idea a reality.
Thanks to DTU Biosustain and Novo Nordisk Foundation for providing the breeding ground for innovation.
More acknowledgments can be found in our preprint.
----
There's a second part to this post:
MillionFull is a foundational technology that serves as the crystallization core for much to build upon.
Our collaboration with the group of Nobel laureate Frances Arnold, a leading lab for integrating machine learning into enzyme engineering workflows, and eXoZymes (Nasdaq: EXOZ), a company with a highly efficient cell-free enzyme prototyping platform, is the prime example.
Based on the massive data enabled by MillionFull, and the cutting-edge ML algorithms developed by the Arnold group (Jason Yang, Sonia Yuan), we've been making exciting progress in the learn and design steps of the Design-Build-Test-(Data)-Learn cycle. ExoZymes' platform (Bastian Vögeli, Tyler Korman, Michael Heltzen) has allowed fast testing of the designed enzyme variants.
Special thanks to Sonia for leading this chapter of the development! Attached is her presenting our progress at the Generative and Experimental Perspectives for Biomolecular Design workshop (https://www.gembio.ai/), part of the ICLR conference at Rio de Janeiro in April.
Meanwhile, our open-sourced dataset has been downloaded ~750 times by the ML protein/enzyme engineering community! We don't know most of the developers, but we look forward with excitement to the fruits of the synergy between big datasets and the right ML approaches built for them.
MillionFull is a technology for obtaining massive full-length enzyme sequence-to-performance datasets, capable of gathering millions of datapoints each run.
The development was motivated by the data drought holding back the exciting potential of AI for enzyme acceleration. The solution came together while I was working as a postdoc at DTU Biosustain. The dataset from the demo run, with >100,000 data points, was open-sourced half a year ago.
With the licensing agreement, we can now apply it to solve real-world problems in biomanufacturing.
Great thanks to Morten Birkeland, our IP advisor, for representing Enzidia in the licensing term discussions, so that we could get to a fair deal structure quickly with clear rationales. I got to learn so much by being the student in the process!
Many thanks to Jens Kindtler and other colleagues on the DTU side for a smooth agreement forming process. We got to see first-hand how DTU executes its mission of "technology for people & society" by supporting research translation.
Great appreciation to Dr. Lei Yang, Prof. Alex Toftgaard Nielsen for their support with scientific input and resources. This work would not have been possible without your recognition and support of new ideas.
Thanks to Bjarke Erichsen and Simon Richter Krarup for helping make the idea a reality.
Thanks to DTU Biosustain and Novo Nordisk Foundation for providing the breeding ground for innovation.
More acknowledgments can be found in our preprint.
----
There's a second part to this post:
MillionFull is a foundational technology that serves as the crystallization core for much to build upon.
Our collaboration with the group of Nobel laureate Frances Arnold, a leading lab for integrating machine learning into enzyme engineering workflows, and eXoZymes (Nasdaq: EXOZ), a company with a highly efficient cell-free enzyme prototyping platform, is the prime example.
Based on the massive data enabled by MillionFull, and the cutting-edge ML algorithms developed by the Arnold group (Jason Yang, Sonia Yuan), we've been making exciting progress in the learn and design steps of the Design-Build-Test-(Data)-Learn cycle. ExoZymes' platform (Bastian Vögeli, Tyler Korman, Michael Heltzen) has allowed fast testing of the designed enzyme variants.
Special thanks to Sonia for leading this chapter of the development! Attached is her presenting our progress at the Generative and Experimental Perspectives for Biomolecular Design workshop (https://www.gembio.ai/), part of the ICLR conference at Rio de Janeiro in April.
Meanwhile, our open-sourced dataset has been downloaded ~750 times by the ML protein/enzyme engineering community! We don't know most of the developers, but we look forward with excitement to the fruits of the synergy between big datasets and the right ML approaches built for them.
Read more
Jinbei Li
May 13
CEO of Messaginglab, Karl Schmieder, MS MFA:
"The scale-up problem in industrial biology isn't an engineering problem. Often, it's a biology problem. Cells are unpredictable by nature but eXoZymes eliminates that variable. When your chemistry runs outside the cell, you can engineer it like a real industrial process."
Full 'Grow Everything' podcast episode with eXoZymes (Nasdaq: EXOZ) CCO, Damien Perriman, available as both video and audio here:
https://lnkd.in/enmBHwSB
#exozymes #cellfree #biomanufacturing
"The scale-up problem in industrial biology isn't an engineering problem. Often, it's a biology problem. Cells are unpredictable by nature but eXoZymes eliminates that variable. When your chemistry runs outside the cell, you can engineer it like a real industrial process."
Full 'Grow Everything' podcast episode with eXoZymes (Nasdaq: EXOZ) CCO, Damien Perriman, available as both video and audio here:
https://lnkd.in/enmBHwSB
#exozymes #cellfree #biomanufacturing
Read more
eXoZymes (Nasdaq: EXOZ)
April 22
This weekend, eXoZymes (Nasdaq: EXOZ) CEO, Michael Heltzen, was interviewed by Don Alexander of GeneCoda® for the 'Executive Insights for Life Sciences Innovator' podcast, under the headline:
"AI-Enabled Cell-Free Biomanufacturing and the Future of Enzyme Engineering"
Check out the full episode here:
https://lnkd.in/e4Pfs-Zh
"AI-Enabled Cell-Free Biomanufacturing and the Future of Enzyme Engineering"
Check out the full episode here:
https://lnkd.in/e4Pfs-Zh
Read more
eXoZymes (Nasdaq: EXOZ)
April 20
eXoZymes (NASDAQ: EXOZ) Chief Commercial Officer Damien Perriman discussed the company’s NCT pilot-scale manufacturing milestone and broader commercialization strategy for cell-free biomanufacturing in a Nasdaq interview filmed at the Nasdaq market site in New York City.
eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at b2idigital.com/exozymes-1.
Interview Highlights:
• 100x pilot-scale manufacturing campaign completed with Cayman Chemical, transferring the company’s process to Cayman’s operators and facility in Michigan
• 99% conversion of raw material to final product
• 99.6% purity achieved in the pilot run
• 12 months from initial development to 100x pilot scale
eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at b2idigital.com/exozymes-1.
Interview Highlights:
• 100x pilot-scale manufacturing campaign completed with Cayman Chemical, transferring the company’s process to Cayman’s operators and facility in Michigan
• 99% conversion of raw material to final product
• 99.6% purity achieved in the pilot run
• 12 months from initial development to 100x pilot scale
Read more
Gideon Lapidoth
May 5
I had a great couple of days in Minneapolis at the BioMADE member meeting.
One of the highlights was joining a panel on cell-free biomanufacturing alongside Christopher Pirie (Decycle Bio), Neeka Mashouf (Rubi Laboratories), Paul Opgenorth (eXoZymes (Nasdaq: EXOZ)), and Alex Rosay (Cascade Bio).
The discussion reinforced something I believe strongly: biology is no longer limited to fermentation. Enzyme-based and cell-free manufacturing are becoming practical industrial tools, capable of making molecules that fermentation cannot reach economically, on timelines measured in weeks rather than years.
For Enzymit, this is exactly the direction we are building toward: a new manufacturing layer that turns abundant carbon feedstocks into the molecules society depends on, across specialty ingredients, materials, fuels, and medicines.
Thank you to Brandon Simmons-Rawls and the BioMADE team for creating space for this conversation and for bringing together such a thoughtful community around the future of biomanufacturing.
If you are working on cell-free systems, enzyme-based production, or new ways to manufacture molecules with biology, I would be happy to connect.
#BioMADE #Biomanufacturing #SyntheticBiology #CellFree #Enzymes #Biocatalysis
One of the highlights was joining a panel on cell-free biomanufacturing alongside Christopher Pirie (Decycle Bio), Neeka Mashouf (Rubi Laboratories), Paul Opgenorth (eXoZymes (Nasdaq: EXOZ)), and Alex Rosay (Cascade Bio).
The discussion reinforced something I believe strongly: biology is no longer limited to fermentation. Enzyme-based and cell-free manufacturing are becoming practical industrial tools, capable of making molecules that fermentation cannot reach economically, on timelines measured in weeks rather than years.
For Enzymit, this is exactly the direction we are building toward: a new manufacturing layer that turns abundant carbon feedstocks into the molecules society depends on, across specialty ingredients, materials, fuels, and medicines.
Thank you to Brandon Simmons-Rawls and the BioMADE team for creating space for this conversation and for bringing together such a thoughtful community around the future of biomanufacturing.
If you are working on cell-free systems, enzyme-based production, or new ways to manufacture molecules with biology, I would be happy to connect.
#BioMADE #Biomanufacturing #SyntheticBiology #CellFree #Enzymes #Biocatalysis
Read more
Gideon Lapidoth
May 5
eXoZymes (NASDAQ: EXOZ) Chief Commercial Officer Damien Perriman discussed the company’s NCT pilot-scale manufacturing milestone and broader commercialization strategy for cell-free biomanufacturing in a Nasdaq interview filmed at the Nasdaq market site in New York City.
eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at b2idigital.com/exozymes-1.
Interview Highlights:
• 100x pilot-scale manufacturing campaign completed with Cayman Chemical, transferring the company’s process to Cayman’s operators and facility in Michigan
• 99% conversion of raw material to final product
• 99.6% purity achieved in the pilot run
• 12 months from initial development to 100x pilot scale
Perriman also discussed plans for additional human use studies on NCT, completion of the company’s GRAS dossier, potential partnerships with marketing players to bring NCT to market, and ongoing work to modify enzymes to create NCT analogues for pharmaceutical applications. He noted that Santalene is already under development as the next product in the company’s pipeline.
“We’ve shown that we can go from idea to 100× pilot scale in 12 months — and hit it right the first time. That kind of speed and predictability is exactly what this industry has been missing, and it’s what turns a single success into a repeatable value engine,” said Damien Perriman, Chief Commercial Officer of eXoZymes.
Watch the Nasdaq interview: https://exozymes.twentythree.com/nasdaq-damien-perriman-interview-on
Read the company’s post: https://exozymes.com/blog/perriman-nasdaq-2026
About eXoZymes: eXoZymes is a Los Angeles, California-based biotechnology company pioneering cell-free biomanufacturing through AI-engineered enzymes that transform sustainable feedstock into nutraceuticals, medicines, and essential chemicals. The company’s proprietary exozyme platform offers a scalable alternative to traditional petrochemical and cell-based production methods, with technology validated through publications in Nature Communications and Nature Chemical Biology.
eXoZymes is led by an experienced management team including Michael Heltzen, CEO; Damien Perriman, CCO; Dr. Tyler Korman, CSO and Co-founder; Dr. Paul Opgenorth, VP of Development and Co-founder; Fouad Nawaz, VP of Finance; Lasse H. Görlitz, VP of Communications; and Amy Lunzer, Chief of Staff.
To learn more about eXoZymes, visit exozymes.com. For investor inquiries, visit exozymes.com/investor.
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser.
eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at b2idigital.com/exozymes-1.
Interview Highlights:
• 100x pilot-scale manufacturing campaign completed with Cayman Chemical, transferring the company’s process to Cayman’s operators and facility in Michigan
• 99% conversion of raw material to final product
• 99.6% purity achieved in the pilot run
• 12 months from initial development to 100x pilot scale
Perriman also discussed plans for additional human use studies on NCT, completion of the company’s GRAS dossier, potential partnerships with marketing players to bring NCT to market, and ongoing work to modify enzymes to create NCT analogues for pharmaceutical applications. He noted that Santalene is already under development as the next product in the company’s pipeline.
“We’ve shown that we can go from idea to 100× pilot scale in 12 months — and hit it right the first time. That kind of speed and predictability is exactly what this industry has been missing, and it’s what turns a single success into a repeatable value engine,” said Damien Perriman, Chief Commercial Officer of eXoZymes.
Watch the Nasdaq interview: https://exozymes.twentythree.com/nasdaq-damien-perriman-interview-on
Read the company’s post: https://exozymes.com/blog/perriman-nasdaq-2026
About eXoZymes: eXoZymes is a Los Angeles, California-based biotechnology company pioneering cell-free biomanufacturing through AI-engineered enzymes that transform sustainable feedstock into nutraceuticals, medicines, and essential chemicals. The company’s proprietary exozyme platform offers a scalable alternative to traditional petrochemical and cell-based production methods, with technology validated through publications in Nature Communications and Nature Chemical Biology.
eXoZymes is led by an experienced management team including Michael Heltzen, CEO; Damien Perriman, CCO; Dr. Tyler Korman, CSO and Co-founder; Dr. Paul Opgenorth, VP of Development and Co-founder; Fouad Nawaz, VP of Finance; Lasse H. Görlitz, VP of Communications; and Amy Lunzer, Chief of Staff.
To learn more about eXoZymes, visit exozymes.com. For investor inquiries, visit exozymes.com/investor.
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser.
Read more
B2i Digital, Inc.
5 days ago
eXoZymes (Nasdaq: EXOZ) CEO Michael Heltzen frames the company’s platform as a new form of chemistry with applications across nutraceuticals and pharmaceuticals.
eXoZymes Inc. (NASDAQ: EXOZ) CEO Michael Heltzen appeared on The Upside to discuss the company’s cell-free biomanufacturing platform, its focus on NCT, and the broader opportunity to apply AI-engineered enzymes outside the cell.
eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1.
Asked about eXoZymes’ growth potential, Heltzen says the company is “here to make it really, really large” and describes the platform as “a new form of chemistry.”
In the full interview, Heltzen discusses NCT, a naturally occurring molecule found in black pepper, and explains how eXoZymes’ platform is designed to produce compounds at scale. He also describes the company’s dual-track opportunity: an over-the-counter nutraceutical path for natural NCT and a pharmaceutical path for more potent analogs.
eXoZymes is a Monrovia, California-based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to transform sustainable feedstocks into high-value compounds. The company is currently focused on products including NCT, non-intoxicating cannabinoids, and other applications where its platform may offer advantages in speed, purity, and scalability.
Learn more at https://exozymes.com. For investor inquiries, visit https://exozymes.com/investor.
Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.
eXoZymes Inc. (NASDAQ: EXOZ) CEO Michael Heltzen appeared on The Upside to discuss the company’s cell-free biomanufacturing platform, its focus on NCT, and the broader opportunity to apply AI-engineered enzymes outside the cell.
eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1.
Asked about eXoZymes’ growth potential, Heltzen says the company is “here to make it really, really large” and describes the platform as “a new form of chemistry.”
In the full interview, Heltzen discusses NCT, a naturally occurring molecule found in black pepper, and explains how eXoZymes’ platform is designed to produce compounds at scale. He also describes the company’s dual-track opportunity: an over-the-counter nutraceutical path for natural NCT and a pharmaceutical path for more potent analogs.
eXoZymes is a Monrovia, California-based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to transform sustainable feedstocks into high-value compounds. The company is currently focused on products including NCT, non-intoxicating cannabinoids, and other applications where its platform may offer advantages in speed, purity, and scalability.
Learn more at https://exozymes.com. For investor inquiries, visit https://exozymes.com/investor.
Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.
Read more
B2i Digital, Inc.
May 8
